Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Notification on Apranga APB Chairman of the Board change
-
China approves HERNEXEOS® as first targeted oral treatment option for HER2-mutant advanced NSCLC at initial diagnosis
-
STORM Therapeutics to Present Promising Phase 1 Sarcoma Data Demonstrating Activity of First‑in‑Class METTL3 Inhibitor STC‑15 at ASCO 2026
-
Together for Steatotic Liver Disease - The Hidden NCDs: SLD as the Next Global Public Health Priority
-
ARKAY Launches New 200 ml Mocktail Tetra Pack Collection: A Convenient, Alcohol-Free Grab-and-Go Beverage for Modern Consumers
-
Syensqo - Participation notification by BlackRock Inc.
-
Casino Group Communication
-
FinVolution Launches 11th Global AI Competition: Teaching Voice AI When to Speak
-
Bekaert - Update on the Share Buyback Program and Liquidity Agreement
-
EXEL Industries: Half-year 2025–2026 results
-
GSET RWA Market Platform Officially Launches, Shaping a New Era of Global Digital Asset Trading
-
Slovenian Tourist Board: Slovenia to Host the 2026 UEC Road European Championships This October
-
NBPE Announces Transaction in Own Shares
-
Progress on ABN AMRO share buyback programme 15 May – 21 May 2026
-
Transaction in Own Shares
-
Equans announces completion of the sale of its EV charging concessions in the Netherlands
-
Ex dividend NOK 1.00 today
-
Holding(s) in Company
-
Aegon appoints Jennifer Palmieri as Chief Human Resources Officer
-
ANGEL Introduces X2 Water Filter System with Advanced Tankless 7-Stage Filtration and 99% PFAS Reduction
-
Renault Group successfully issues dual-tranche samurai bonds for a nominal amount of ¥159 billion
-
CROSSJECT announces the successful completion of an equity financing and warrant issuance for a total immediate gross amount of €15 million
-
-
-
FRO – First Quarter 2026 Results
-
OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer
-
Richemont delivers strong sales growth and solid results for the year ended 31 March 2026
-
Richemont announces the end of the share buyback programme initiated in May 2023 and the launch of a new programme
-
Information relating to the total number of voting rights and share capital - April 30, 2026
-
Cricbet99 Announces User Accessibility Support Initiative to Help Resolve Common Login Issues
-
Start of Day Message
-
VALLOUREC AND SYNGULAR SOLUTIONS SIGN A MEMORANDUM OF UNDERSTANDING TO ACCELERATE THE DEVELOPMENT OF BIOENERGY WITH CARBON CAPTURE AND STORAGE PROJECTS
-
Mowi ASA: Ex-dividend NOK 2.30 today
-
VOOPOO’s ARGUS G4 & ARGUS G4 mini: One Cartridge, Triple Vibes
-
Novo Announces Director Election Results
-
NervGen Announces Pricing of US$60.0 Million Public Offering of Securities
-
Yimutian Inc. Announces Submission of Hearing Request to Nasdaq and Proactive Measures to Regain Full Compliance
-
Medline Inc. announces pricing of upsized secondary offering of Class A common stock
-
GLOBAL’s AcceptAbility Gala Raises $430,000 for Down Syndrome Research and Medical Care as Celebrities and Congressional Leaders Rally Behind the Cause
-
AIFA Provides Update on Nasdaq Notice and Filing of Annual Report, Clearing Key Pathways for Strategic Transformation
-
Crypto News: AlphaPepe Presale Q2 PancakeSwap Listing Nears as Bitcoin Price Prediction Targets $200,000
-
Fushi Tech Unveils AI Agent Strategy Targeting Overseas Merchants
-
Liminatus Pharma Announces Nasdaq Delisting Notification
-
Peyto Exploration & Development Corp. Announces Voting Results From Annual General Meeting of Shareholders
-
Purecore Engages HEG & Associates for its 2026 Exploration Program at the Bankier Property
-
Rocket Lab Awarded $90M Contract to Build GEO Satellites Hosting Space Domain Awareness Payload for U.S. Space Force
-
Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026
-
Rocket Lab Awarded $90M Contract to Build GEO Satellites Hosting Space Domain Awareness Payload for U.S. Space Force
-
HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting
-
TaiMed Biologics Completes Phase 2b Enrollment for TMB-365/380 in HIV Maintenance Therapy Study

